Sign up to save your podcasts
Or
Share S2 Ep43: GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S2 Ep43: GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Drs Stacey Cohen, Aparna Parikh, Kanwal Raghav, and John Strickler discuss advancements in targeted therapies to treat adult metastatic colorectal cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Pfizer, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 4921
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
John H. Strickler, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University
Durham, NC
Co-Leader, Duke Molecular Tumor Board
Associate Director Clinical Research, GI
Duke Cancer Institute
Durham, NC
Disclosures: Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson & Johnson, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Regeneron, Roche/Genentech, Sanofi, Taiho, Takeda, Triumvira, Xilio Therapeutics; Research: AbbVie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech.
Faculty:
Stacey A. Cohen, MD
Associate Professor, Division of Hematology/Oncology
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Consultant: AbbVie, Agenus, DoMore Diagnostics, Exact Sciences, GSK, Guardant, Incyte, Janssen, Merck, Pfizer, Roche; IDMC Member: GSK.
Aparna Parikh, MD
Associate Professor of Medicine
Harvard Medical School
Director, Global Cancer Care Program
Massachusetts General Hospital
Boston, MA
Disclosures: Adviser/Consultant: 3T Biosciences, AbbVie, Adroya Sciences, Amgen, Astra Zeneca, Bristol Myers Squibb, Caris, CareSet, CVS, Delicate, DoMore Diagnostics, Eli Lilly, Exact, Foundation Medicine, GSK, Guardant, Hookipa, Incyte, Kahr, Merck, Mirati, MPM Capital, Natera, Parithera, Pfizer, Phesi, PMV, Regeneron, Scare, Science for America, Seagen, Sirtex, Summit Therapeutics, Takeda, Third Rock Ventures, Value Analytics Labs, Xilio, Zola; Chief Scientist: Reversing Early Recurrence; Fees: Up to Date; Research Funding (to institution): Bristol Myers Squibb, Daiichi Sankyo, Erasca, Genentech, Mirati, Parthenon, PMV Pharmaceuticals, Revolution Medicine, Syndax; Shareholder: C2i Genomics, Cadex, Khora, OneCell, Parithera, XGenomes; Travel Fees: Karkinos Healthcare.
Kanwal P.S. Raghav, MBBS, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory board: AstraZeneca, Daiichi Sankyo, Pfizer; Research Funding: AstraZeneca, Daiichi Sankyo.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on clinical trial data for targeted therapies in mCRC, go to https://www.gotoper.com/annual-oncology-meeting-25-mcrc-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
View all episodes
By PER® SpectivesThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Drs Stacey Cohen, Aparna Parikh, Kanwal Raghav, and John Strickler discuss advancements in targeted therapies to treat adult metastatic colorectal cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Pfizer, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 4921
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
John H. Strickler, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University
Durham, NC
Co-Leader, Duke Molecular Tumor Board
Associate Director Clinical Research, GI
Duke Cancer Institute
Durham, NC
Disclosures: Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson & Johnson, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Regeneron, Roche/Genentech, Sanofi, Taiho, Takeda, Triumvira, Xilio Therapeutics; Research: AbbVie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech.
Faculty:
Stacey A. Cohen, MD
Associate Professor, Division of Hematology/Oncology
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Consultant: AbbVie, Agenus, DoMore Diagnostics, Exact Sciences, GSK, Guardant, Incyte, Janssen, Merck, Pfizer, Roche; IDMC Member: GSK.
Aparna Parikh, MD
Associate Professor of Medicine
Harvard Medical School
Director, Global Cancer Care Program
Massachusetts General Hospital
Boston, MA
Disclosures: Adviser/Consultant: 3T Biosciences, AbbVie, Adroya Sciences, Amgen, Astra Zeneca, Bristol Myers Squibb, Caris, CareSet, CVS, Delicate, DoMore Diagnostics, Eli Lilly, Exact, Foundation Medicine, GSK, Guardant, Hookipa, Incyte, Kahr, Merck, Mirati, MPM Capital, Natera, Parithera, Pfizer, Phesi, PMV, Regeneron, Scare, Science for America, Seagen, Sirtex, Summit Therapeutics, Takeda, Third Rock Ventures, Value Analytics Labs, Xilio, Zola; Chief Scientist: Reversing Early Recurrence; Fees: Up to Date; Research Funding (to institution): Bristol Myers Squibb, Daiichi Sankyo, Erasca, Genentech, Mirati, Parthenon, PMV Pharmaceuticals, Revolution Medicine, Syndax; Shareholder: C2i Genomics, Cadex, Khora, OneCell, Parithera, XGenomes; Travel Fees: Karkinos Healthcare.
Kanwal P.S. Raghav, MBBS, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory board: AstraZeneca, Daiichi Sankyo, Pfizer; Research Funding: AstraZeneca, Daiichi Sankyo.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on clinical trial data for targeted therapies in mCRC, go to https://www.gotoper.com/annual-oncology-meeting-25-mcrc-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.